Sorafenib for the treatment of progressive, locally advanced or metastatic, differentiated (papillary/follicular/hürthle cell) Thyroid Carcinoma, refractory to radioactive Iodine
Country | Agency | Status | Link | Details on adaptation | Contact information |
|---|---|---|---|---|---|
(Scotland) | HIS | Published July 2015 | Link to report | The EUnetHTA report was referenced in discussion on impact of sorafenib on health related quality of life. | Jan Jones
janjones@nhs.net |
Belgium | RIZIV | Used in cross-checking evidence. | Francis Arickx
francis.arickx@riziv.fgov.be | ||
Belgium | KCE | Link to summary | Analysis of scientific context and its relevance, “KCE has read for you”. | Patrice Chalon
patrice.chalon@kce.fgov.be | |
Croatia | AAZ | 2015 | Summary of information from the report for decision makers and website | Mirjana Huic (Mirjana.Huic@aaz.hr) | |
Portugal | INFARMED | Used in direct decision-making. | João Martins
joao.martins@infarmed.pt | ||
Slovakia | MoH SK | Used in direct decision-making. | Tomas Tesar
tomas.tesar@union.sk | ||
Spain | IACS | Used in direct decision-making. | Almudena Albertos
aalbertos@isciii.es |
